Modification of the tumor microenvironment in KRAS or c-MYC-induced ovarian cancer-associated peritonitis

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Yoshida, Mitsuyo ^a   Taguchi, Ayumi ^a   Kawana, Kei ^a   Adachi, Katsuyuki ^a   Kawata, Akira ^a   Ogishima, Juri ^a   Nakamura, Hiroe ^a   Fujimoto, Asaha ^a   Sato, Masakazu ^a   Inoue, Tomoko ^a   Nishida, Haruka ^a   Furuya, Hitomi ^a   Tomio, Kensuke ^a   Arimoto, Takahide ^a   Koga, Kaori ^a   Wada Hiraike, Osamu ^a   Oda, Katsutoshi ^a   Nagamatsu, Takeshi ^a   Kiyono, Tohru ^b   Osuga, Yutaka ^a   Fujii, Tomoyuki ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VASCULOTROPIN; KRAS2 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; PROTEIN P21; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; C57BL 6 MOUSE; CANCER GROWTH; DISEASE COURSE; GENETIC TRANSDUCTION; ID8 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL COUNT; NONHUMAN; ONCOGENE C MYC; ONCOGENE K RAS; OVARIAN CANCER ASSOCIATED PERITONITIS; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONITIS; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ASCITES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PERITONITIS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84982095840     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160330     Document Type: Article

References (32)

1. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 2002 Sep; 3(9):537-45. PMID: 12217791
2. Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H,et al.A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol (2014) 73:895-901 doi: 10.1007/s00280-014-2418-8 PMID: 24585045
3. Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol.2012 Oct; 17(5):430-40. doi: 10.1007/s10147-012-0459-8 PMID: 22926640
4. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, et al. An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin invest.2012 2; 122(4):1519-28. doi: 10.1172/JCI59743 PMID: 22406536
5. Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014 Feb; 77(2):128-36. doi: 10.1016/j.maturitas.2013.11.009 PMID: 24380827
6. Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling. Nat Commun. 2015 Jan 27; 6:6118. doi: 10.1038/ncomms7118 PMID: 25625625
7. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 2014 Jan 21; 110(2):469-78. doi: 10.1038/bjc.2013.748 PMID: 24346288
8. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013; 73:2480-2492 doi: 10.1158/0008-5472.CAN-12-3542 PMID: 23436796
9. Nelson BH. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr Opin Immunol. 2015 Apr; 33:93-100. doi: 10.1016/j.coi.2015.02.004 PMID: 25710852
10. Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H,et al., Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis, 2009. 30(3): p. 423-31. doi: 10.1093/carcin/bgp007 PMID: 19126650
11. Pikaart M.J., Recillas-Targa F., and Felsenfeld G., Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev, 1998. 12(18): p. 2852-62. PMID: 9744862
12. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O,et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000 Apr; 21(4):585-91. PMID: 10753190
13. Huang Z, Huang S, Wang Q, Wang Q, Liang L, Ni S, et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 2011; 71:2582-2589. doi: 10.1158/0008-5472.CAN-10-3032 PMID: 21427358
14. Taguchi A, Kawana K, Tomio K, Yamashita A, Isobe Y, Nagasaka K, et al. Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS One. 2014 Feb 27; 9(2):e89605. doi: 10.1371/journal.pone.0089605 PMID: 24586907
15. Taguchi A, Wada-Hiraike O, Kawana K, Koga K, Yamashita A, Shirane A, et al. Resveratrol suppress inflammatory responses in endometrial stromal sells derived endometriosis:Apossible role of sirtuin 1 pathway. Jurnal of Obstetrics and Gynecology Research.Volume 40, Issue 3, pages770-778.March 2014.
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17; 357(9255):539-45. PMID: 11229684
17. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol.2002. 196, 254-265. PMID: 11857487
18. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer.Nat Rev Cancer. 2008; 8:51-6. PMID: 18046334
19. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6. PMID: 1688381
20. Liang B, Guo Z, Li Y, Liu C. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013 Mar 11.
21. Şahin N, Apaydin N, Töz E, Sivrikoz ON, Genç M, Turan GA, et al. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch Gynecol Obstet. 2015 Dec 21.
22. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004 Nov; 6(5):447-58. PMID: 15542429
23. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene. 2006 Mar 30; 25(14):2105-12. PMID: 16288213
24. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014 Aug 26; 111(5):817-22. doi: 10.1038/bjc.2014.215 PMID: 24755884
25. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011 Oct 13; 11(11):761-74. doi: 10.1038/nrc3106 PMID: 21993244
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357:539-545. PMID: 11229684
27. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011 Jan 15; 71(2):424-34. doi: 10.1158/0008-5472.CAN-10-1496 PMID: 21123455
28. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011 May; 1813(5):878-88. doi: 10.1016/j.bbamcr.2011.01.034 PMID: 21296109
29. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29; 106(6):dju124. doi: 10.1093/jnci/dju124 PMID: 24875653
30. Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, et al. Pretreatment neutrophilto-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study. Int J Urol. 2015 Jul; 22(7):638-43. doi: 10.1111/iju.12766 PMID: 25903328
31. Khajah M, Millen B, Cara DC, Waterhouse C, McCafferty DM. Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo. J Leukoc Biol. 2011 Jun; 89(6):945-53. doi: 10.1189/jlb.0809546 PMID: 21393420
32. Fossati G, Mazzucchelli I, Gritti D, Ricevuti G, Edwards SW, Moulding DA, et al. In vitro effects of GM-CSF on mature peripheral blood neutrophils. Int J Mol Med. 1998 Jun; 1(6):943-51. PMID: 9852629